ライフサイエンスコーパス: placebo group

1 cidence of ALRI hospitalizations was similar in the IIV and placebo group for infants >3 months of age.

2 Vitamin D and placebo groups did not differ in change in insulin sensitivit

3 que volumes at 1 year were similar between the ramipril and placebo groups (162.1 +/- 70.5 mm(3) vs. 177.3 +/- 94.3 mm(3)

4 s or laboratory abnormalities between the PfSPZ Vaccine and placebo groups, and only grade 1 (mild) local or systemic adv

5 gemcitabine (vandetanib group) or placebo plus gemcitabine (placebo group) according to pre-generated sequences produced

6 significant changes occurred within the anakinra 2-week or placebo groups.

7 dverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-y

8 ted median difference between the cannabidiol group and the placebo group in change in seizure frequency, -22.8 percentag

9 ght gain in the trimethoprim-sulfamethoxazole group and the placebo group was similar (mean [SD] change in weight-for-age

10 as -3.2 for the 80 mg/day group, compared with -0.1 for the placebo group, a significant difference.

11 nction) was greater in the angiotensin II group than in the placebo group (-1.75 vs. -1.28, P=0.01).

12 .99 points in the prednisolone group and 2.16 points in the placebo group (adjusted difference, -0.20; 95% CI, -0.40 to 0

13 9%) in the vitamin D3 + calcium group and 64 (5.58%) in the placebo group (difference, 1.69% [95% CI, -0.06% to 3.46%]; P

14 angiotensin II group and in 85 of 158 patients (54%) in the placebo group (hazard ratio, 0.78; 95% CI, 0.57 to 1.07; P=0.

15 96 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [C

16 in the buparlisib group versus 4.0 months (3.1-5.2) in the placebo group (HR 0.76 [0.60-0.97], one-sided p=0.014).

17 ) in the canakinumab-treated group (n = 5 of 7) than in the placebo group (n = 0 of 13).

18 ab groups, respectively, as compared with 2.4 points in the placebo group (P<0.001 for each dose vs. placebo), and everyd

19 ab groups, respectively, as compared with 3.3 points in the placebo group (P<0.001 for each dose vs. placebo).

20 he tranexamic acid group and in 2.8% of the patients in the placebo group (P=0.001), and seizures occurred in 0.7% and 0.

21 reased (P=0.003) more in the elamipretide group than in the placebo group (P=0.11).

22 1 year in the Hypothyroid Symptoms score (0.2+/-15.3 in the placebo group and 0.2+/-14.4 in the levothyroxine group; betw

23 aths at age 0-6 months was similar in each group (50 in the placebo group and 61 in the vaccine group).

24 Five women died in the placebo group and three died in the vaccine group.

25 One patient in the placebo group died (unrelated to study treatment).

26 e medium-dose group, 3 in the high-dose group, and 1 in the placebo group discontinued the trial regimen because of adver

27 At 6 months, improvement persisted in 1 patient in the placebo group versus 3 of 4 in the rituximab group, where the

28 duals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment

29 patients in the brexanolone group vs three patients in the placebo group) and somnolence (two vs none).

30 nts in the olaparib group vs two [2%] of 99 patients in the placebo group), fatigue or asthenia (eight [4%] vs two [2%]),

31 [11%] of 70 in the masitinib group vs one [2%] of 63 in the placebo group), rash (four [6%] vs none), and asthenia (four

32 However, in the placebo group, but not in the propranolol group, memory vivid

33 exacerbations was 27% lower in the active group than in the placebo group, but this did not reach significance (estimated

34 ents had 11 serious adverse events: one (2%) patient in the placebo group, three (5%) in the low-dose group, and two (3%)

35 ificantly more common in the canakinumab groups than in the placebo group.

36 tients in the olaparib group and eight (8%) patients in the placebo group.

37 n the 170-mug group became nonreactive to CPT vs 18% in the placebo group.

38 zziness was more common in the pregabalin group than in the placebo group.

39 MMP9 were significantly higher in the VD group than in the placebo group.

40 significantly lower in the sotagliflozin group than in the placebo group.

41 phatemia were more common in the imatinib group than in the placebo group.

42 Survey (median score, 0 in the sertraline group vs 0 in the placebo group; between-group difference, 0 [95% CI, -10.0 to

43 3 + calcium group and 0.060 (95% CI, 0.048 to 0.076) in the placebo group; P = .06.

44 ients in the buparlisib group versus 23 (16%) of 140 in the placebo group; the most frequent serious adverse events (affe

45 284 were randomized (146 to the active group and 138 to the placebo group).

46 controlled trial, we randomly allocated 172 57 (33%) to the placebo group, 57 (33%) to the low-dose group, and 58 (34%) t

47 ipants were assigned to the minocycline group and 70 to the placebo group.

48 -serotype E coli was noted in the vaccine compared with the placebo group (0.149 mean episodes vs 0.146 mean episodes; p=

49 tion was reported in the idelalisib group compared with the placebo group (grade >/=3 infections and infestations: 80 [39

50 a mean increase in quality of life score compared with the placebo group.